2009
DOI: 10.1590/s1980-57642009dn30100012
|View full text |Cite
|
Sign up to set email alerts
|

Charles Bonnet Syndrome: Case series

Abstract: Since its first description in 1760, Charles Bonnet syndrome (CBS) has been reported in many studies. The main characteristics are visual hallucinations, preserved awareness of unreal visions, and absence of psychotic symptoms. CBS can occur with lesions located anywhere along the central visual pathway, from the eye to the calcarine fissure.ObjectiveTo describe patients with CBS and carry out a review of the literature.MethodsSix patients with visual hallucinations were evaluated in an outpatient memory clini… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
18
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(18 citation statements)
references
References 46 publications
0
18
0
Order By: Relevance
“…In ffytche and Howard series 9 , tesellopsia ocurred in 74% and abnormalities of size in 42% of their patients, of whom 58% had micropsia. In Brucki et al 10 series, tesellopsia, micropsia, prosopometamorphopsia and polyopsia were observed.…”
Section: Discussionmentioning
confidence: 92%
See 2 more Smart Citations
“…In ffytche and Howard series 9 , tesellopsia ocurred in 74% and abnormalities of size in 42% of their patients, of whom 58% had micropsia. In Brucki et al 10 series, tesellopsia, micropsia, prosopometamorphopsia and polyopsia were observed.…”
Section: Discussionmentioning
confidence: 92%
“…Notwithstanding a directed questionnaire, a mean delay in diagnosis of almost 42 months indicates that our patients were younger than the elderly patients described in literature. In another Brazilian case series of CBS, Brucki et al 10 described six patients with a mean age of 74.5 years.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…If improvement does not occur, first step should be the management of cause of visual loss if possible. If needed, neuroleptics, anticonvulsants, antidepressants, benzodiazepines and cognitive enhancer agents such as cholinesterase inhibitors can be used [3,8,15,16]. Our patient has also been treated successfully with a neuroleptic agent, 0.5 milligram/day risperidone.…”
Section: Discussionmentioning
confidence: 92%
“…If patients are not bothered by visual hallucinations, treatment may also not be necessary. Only education and reassurance of the benign nature of the events, improving the quality of life may be enough for the patients [8,15]. Hallucinations may also resolve spontaneously [6].…”
Section: Discussionmentioning
confidence: 99%